D.E. Shaw & Co
INO icon

D.E. Shaw & Co’s Inovio Pharmaceuticals INO Stock Holding History

D.E. Shaw & Co’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.85M Sell
2,212,819
-18,992
-0.9% -$31.3K ﹤0.01% 2381
2025
Q4 		$3.88M Buy
2,231,811
+1,425,069
+177% +$3.14M ﹤0.01% 2516
2025
Q3 		$1.89M Buy
+806,742
New +$1.54M ﹤0.01% 3023
2024
Q1 		– Sell
-225,097
Closed -$1.38M – 4522
2023
Q4 		$1.38M Sell
225,097
-234,806
-51% -$1.16M ﹤0.01% 2920
2023
Q3 		$2.15M Sell
459,903
-173,608
-27% -$959K ﹤0.01% 2512
2023
Q2 		$3.39M Buy
633,511
+81,941
+15% +$661K ﹤0.01% 2182
2023
Q1 		$5.43M Sell
551,570
-154,322
-22% -$2.63M 0.01% 1865
2022
Q4 		$13.2M Buy
705,892
+76,655
+12% +$1.74M 0.01% 1196
2022
Q3 		$13M Buy
629,237
+129,383
+26% +$3.31M 0.02% 1147
2022
Q2 		$10.4M Buy
499,854
+41,535
+9% +$1.17M 0.01% 1362
2022
Q1 		$19.7M Sell
458,319
-40,475
-8% -$1.82M 0.02% 1042
2021
Q4 		$29.9M Buy
498,794
+182,723
+58% +$14.6M 0.02% 829
2021
Q3 		$27.2M Buy
316,071
+141,916
+81% +$14.2M 0.02% 836
2021
Q2 		$19.4M Buy
174,155
+98,121
+129% +$9.42M 0.02% 1037
2021
Q1 		$8.47M Buy
76,034
+2,292
+3% +$301K 0.01% 1472
2020
Q4 		$7.83M Buy
73,742
+50,011
+211% +$6.66M 0.01% 1533
2020
Q3 		$3.3M Sell
23,731
-12,111
-34% -$2.53M ﹤0.01% 1998
2020
Q2 		$11.6M Buy
+35,842
New +$5.76M 0.01% 1107
2020
Q1 		– Sell
-35,373
Closed -$1.4M – 4081
2019
Q4 		$1.4M Buy
35,373
+18,024
+104% +$542K ﹤0.01% 2750
2019
Q3 		$426K Sell
17,349
-12,096
-41% -$368K ﹤0.01% 3288
2019
Q2 		$1.04M Sell
29,445
-54,963
-65% -$2.18M ﹤0.01% 2654
2019
Q1 		$3.78M Sell
84,408
-5,016
-6% -$253K ﹤0.01% 1736
2018
Q4 		$4.29M Buy
89,424
+49,724
+125% +$3.02M 0.01% 1608
2018
Q3 		$2.65M Buy
39,700
+26,084
+192% +$1.45M ﹤0.01% 2005
2018
Q2 		$640K Sell
13,616
-12,436
-48% -$686K ﹤0.01% 2973
2018
Q1 		$1.47M Buy
26,052
+3,594
+16% +$195K ﹤0.01% 2246
2017
Q4 		$1.11M Sell
22,458
-26,534
-54% -$1.64M ﹤0.01% 2514
2017
Q3 		$3.73M Buy
48,992
+30,556
+166% +$2.27M 0.01% 1595
2017
Q2 		$1.74M Buy
+18,436
New +$1.58M ﹤0.01% 2059
2017
Q1 		– Sell
-3,160
Closed -$263K – 3435
2016
Q4 		$263K Sell
3,160
-529
-14% -$47.8K ﹤0.01% 3163
2016
Q3 		$413K Sell
3,689
-221
-6% -$24.4K ﹤0.01% 2889
2016
Q2 		$434K Buy
3,910
+971
+33% +$118K ﹤0.01% 2850
2016
Q1 		$307K Sell
2,939
-2,797
-49% -$216K ﹤0.01% 3008
2015
Q4 		$463K Buy
5,736
+2,903
+102% +$231K ﹤0.01% 3132
2015
Q3 		$197K Sell
2,833
-6,146
-68% -$536K ﹤0.01% 3504
2015
Q2 		$879K Buy
8,979
+232
+3% +$24.8K ﹤0.01% 2797
2015
Q1 		$856K Sell
8,747
-4,236
-33% -$410K ﹤0.01% 2679
2014
Q4 		$1.43M Buy
+12,983
New +$1.59M ﹤0.01% 2553

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's INO Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Inovio Pharmaceuticals (INO) stake by 0.85% in Q1 2026, selling an estimated $31.3K and leaving 2,212,819 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2381.

D.E. Shaw & Co first reported a position in INO in Q4 2014 and has held it in 38 quarters since. The position peaked at $29.9M in Q4 2021. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • D.E. Shaw & Co held 2,212,819 shares of Inovio Pharmaceuticals worth $3.85M as of Q1 2026.
  • D.E. Shaw & Co sold 18,992 Inovio Pharmaceuticals shares in Q1 2026, an estimated $31.3K.
  • Inovio Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2381 holding.
  • D.E. Shaw & Co first reported a position in Inovio Pharmaceuticals in Q4 2014 and has held it in 38 quarters since.
  • D.E. Shaw & Co's Inovio Pharmaceuticals position peaked at $29.9M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.